Interview with Petr Tor, Country Director, Stallergenes Czech Republic
Mr. Tor, prior to joining Stallergenes in 2010, you had been with MSD for nearly two decades. After such a prolonged experience at a major global pharma player, why did…
Address: Belgicka 20 – 120 00 Praha 2 ,Czech Republic
Tel: +420 222 515 342
Web: http://www.stallergenes.cz/
Stallergenes is a European biopharmaceutical company specialised in the treatment by allergen immunotherapy of allergy related respiratory diseases, such as severe rhinoconjunctivitis and rhinitis, as well as allergic asthma. A pioneer and a leader in immunotherapy treatments by sublingual administration, Stallergenes dedicates nearly 20% (gross) of its sales to its Research and Development activities, which are primarily directed at developing a new therapeutic range: sublingual immunotherapy tablets. In 2011, the company had sales of € 235 million and more than 500,000 patients were treated with Stallergenes products.
Sublingual immunotherapy tablets
NPPs
Diagnosis products
Mr. Tor, prior to joining Stallergenes in 2010, you had been with MSD for nearly two decades. After such a prolonged experience at a major global pharma player, why did…
Martin Mátl, executive director of the Czech Association of Pharmaceutical Companies (ČAFF), shares the key priorities and challenges of the association and its members; assesses the Czech generics ecosystem, and…
CzechBio’s Serhiy Forostyak, MD, Ph.D, shares the importance of a strong platform where all actors of the biotech landscape can develop their ideas and establish valuable partnerships on a national…
Despite being recently divested from multinational pharma giant Sanofi, Czech firm Zentiva is becoming one of the fastest-growing generics manufacturing companies in Europe, with a swathe of recent international acquisitions…
The Czech Republic is aiming to carve out a space for itself among Europe’s most innovative countries by 2030 as part of the ‘Innovation Strategy of the Czech Republic 2019–2030.’…
One of the very first former-communist European states to attain a successful economic transition, the Czech Republic today puts across a compelling argument for being regarded as one of the…
Entrepreneurially-minded individuals, together with academic institutions with their fingers on the pulses of the latest trends, are propelling Czech pharma companies to great success and cementing the Czech Republic at…
Novartis Czech Republic’s Heidrun Irschik explains the potentially game-changing ramifications of Big Data on the Czech pharmaceutical and healthcare industries. The opportunities offered by big data are present and…
The general manager of ALK Czech Republic and Slovakia on his strategy which led to success within the first one and a half years of ALK’s physical presence in the…
Reckitt Benckiser’s General Manager for the CEE region, Lajos Magyari, discusses the strength of the company’s current portfolio, the importance of innovation and the success factors he focuses on to…
The general manager of Wörwag Pharma Czech Republic & Slovakia reviews to what degree the Czech and Slovak market are homogeneous and which strategies can be successfully transferred from one…
There is frequent dialogue between the pharmaceutical industry, relevant regulatory authorities, and government stakeholders in the Czech Republic, but this dialogue is often strained. However, more frequent and constructive interaction between…
Women’s health is an increasingly significant niche for pharma companies operating in the Czech Republic, with large areas of unmet need and opportunities for growth. We have great expectations…
See our Cookie Privacy Policy Here